Yahoo Finance Celadon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)
Celadon Pharmaceuticals (LON:CEL) First Half 2023 Results
Key Financial Results
Net loss: UK£4.30m (loss narrowed by 68% from 1H 2022).
UK£0.07 loss per share (improved from UK£0.25 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Celadon Pharmaceuticals shares are down 10% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Celadon Pharmaceuticals (including 3 which shouldn't be ignored).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
